Long-Term Registry Following People With Alzheimer's and Related Dementias
Collects routine clinical information from adults with Alzheimer's disease over many years.
Plain-language title generated from the registry record
Registry title: InRAD Observational Study
Key facts
- Where
- Leuven, BelgiumSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- How old are you?
Source: NCT07213700, who can take part
Where in Belgium
- UZLeuvenLeuven, BelgiumTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Stichting International Registry for Alzheimer's Disease and other Dementias Foundation
- Trial code
- NCT07213700
- Record updated
- 6 November 2026
- Original description
The goal of this international observational study is to evaluate long-term disease outcomes and treatment safety in people with Alzheimer's disease (PwAD), by collecting real-world data from routine clinical practice across global clinical centers.Read full original descriptionShow less
The International Registry for Alzheimer's Disease and Other Dementias (InRAD): An International Registry Observational Study Dedicated to Evaluating Outcomes Data in Alzheimer's Disease
The goal of this international observational study is to evaluate long-term disease outcomes and treatment safety in people with Alzheimer's disease (PwAD), by collecting real-world data from routine clinical practice across global clinical centers.
The InRAD Registry Observational Study has several aims:
* To collect medical information for many years from a large group of people with Alzheimer's disease. This will be used for research, which will support improved understanding about the disease. * To enable researchers to look at the effectiveness, usefulness and safety of treatments for Alzheimer's disease. * To enable researchers to answer similar research questions and compare results in many different areas of the world.
People with Alzheimer's disease who meet the eligibility criteria and agree to participate in the Study will be asked to visit their doctor (e.g. psychiatrist, geriatrician, or neurologist) at least once a year, or as frequently as is needed for their care. During or after their appointments they may be offered assessments, tests, medications, and treatments as determined by their doctor and their team. This is an observational data collection.
Inclusion: Be undergoing diagnostic work-up for Alzheimer's disease (AD), OR; Have a confirmed diagnosis of AD (whether currently treated with an AD-specific treatment, or untreated),; Be attending an InRAD Center,; Have provided informed consent for long-term follow-up.
Exclusion: The protocol does not specify a lower or upper age limit. Participants are expected to be predominantly adults, and can include younger adults with early-onset or genetically determined Alzheimer's disease (e.g. Down syndrome-associated Alzheimer's disease); -Any patient or legal representative who is unable or unwilling to provide a signed informed consent form.